Ghent University Academic Bibliography

Advanced

Population screening for prostate cancer: an overview of available studies and meta-analysis

Nicolaas Lumen UGent, VALERIE FONTEYNE UGent, Gert De Meerleer UGent, Piet Ost UGent, Geert Villeirs UGent, Alexandre Mottrie, PIETER DE VISSCHERE UGent, BART DE TROYER UGent and Willem Oosterlinck UGent (2012) INTERNATIONAL JOURNAL OF UROLOGY. 19(2). p.100-108
abstract
The objective of the present review was to evaluate the effect of population-based screening on the incidence of prostate cancer, prostate cancer tumor stage and grade, prostate cancer mortality, and overall mortality. A systematic review was carried out in April 2011, searching the Medline and Web of Science databases. The records were reviewed to identify comparative and randomized controlled trials evaluating the effect of screening on prostate cancer. Eight trials were identified containing personalized data on a screened versus a non-screened cohort. Prostate-specific antigen and digital rectal examination were the main screening tools. Prostate-specific antigen threshold and screening interval was not uniform among the different trials. Screening was associated with a significant increase in prostate cancer detection (relative risk 1.55; P = 0.002), and a significant shift towards more localized (relative risk 1.81; P = 0.01) and more low-grade tumors (relative risk 2.32; P = 0.001). In overall analysis, no significant effect on prostate cancer mortality (relative risk 0.88; P = 0.18) and overall mortality (relative risk 0.90; P = 0.27) in favor of screening was observed. An adjusted analysis excluding papers with short follow up, high prostate-specific antigen contamination in the non-screening group and low participation in the screening group was able to show a significant reduction in prostate cancer mortality of 24%. The ideal screening strategy is unclear. Screening is associated with better PC detection and this in a more localized stage and of less aggressive tumors. Excluding the main shortcomings in screening studies (short follow up, high prostate-specific antigen contamination in non-screening group and low participation in screening group), screening is able to reduce prostate cancer mortality.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (review)
publication status
published
subject
keyword
MEN, PSA, OUTCOMES, LEVEL, ANTIGEN, MORTALITY, DECREASES, CONSERVATIVE MANAGEMENT, FOLLOW-UP, RANDOMIZED CONTROLLED-TRIAL, screening, prostate cancer, prostate-specific antigen, prostate biopsy, early diagnosis
journal title
INTERNATIONAL JOURNAL OF UROLOGY
Int. J. Urol.
volume
19
issue
2
pages
100 - 108
Web of Science type
Review
Web of Science id
000299417900003
JCR category
UROLOGY & NEPHROLOGY
JCR impact factor
1.734 (2012)
JCR rank
35/73 (2012)
JCR quartile
2 (2012)
ISSN
0919-8172
DOI
10.1111/j.1442-2042.2011.02912.x
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
2028734
handle
http://hdl.handle.net/1854/LU-2028734
date created
2012-02-13 16:57:21
date last changed
2012-03-02 10:33:32
@article{2028734,
  abstract     = {The objective of the present review was to evaluate the effect of population-based screening on the incidence of prostate cancer, prostate cancer tumor stage and grade, prostate cancer mortality, and overall mortality. A systematic review was carried out in April 2011, searching the Medline and Web of Science databases. The records were reviewed to identify comparative and randomized controlled trials evaluating the effect of screening on prostate cancer. Eight trials were identified containing personalized data on a screened versus a non-screened cohort. Prostate-specific antigen and digital rectal examination were the main screening tools. Prostate-specific antigen threshold and screening interval was not uniform among the different trials. Screening was associated with a significant increase in prostate cancer detection (relative risk 1.55; P = 0.002), and a significant shift towards more localized (relative risk 1.81; P = 0.01) and more low-grade tumors (relative risk 2.32; P = 0.001). In overall analysis, no significant effect on prostate cancer mortality (relative risk 0.88; P = 0.18) and overall mortality (relative risk 0.90; P = 0.27) in favor of screening was observed. An adjusted analysis excluding papers with short follow up, high prostate-specific antigen contamination in the non-screening group and low participation in the screening group was able to show a significant reduction in prostate cancer mortality of 24\%. The ideal screening strategy is unclear. Screening is associated with better PC detection and this in a more localized stage and of less aggressive tumors. Excluding the main shortcomings in screening studies (short follow up, high prostate-specific antigen contamination in non-screening group and low participation in screening group), screening is able to reduce prostate cancer mortality.},
  author       = {Lumen, Nicolaas and FONTEYNE, VALERIE and De Meerleer, Gert and Ost, Piet and Villeirs, Geert and Mottrie, Alexandre and DE VISSCHERE, PIETER and DE TROYER, BART and Oosterlinck, Willem},
  issn         = {0919-8172},
  journal      = {INTERNATIONAL JOURNAL OF UROLOGY},
  keyword      = {MEN,PSA,OUTCOMES,LEVEL,ANTIGEN,MORTALITY,DECREASES,CONSERVATIVE MANAGEMENT,FOLLOW-UP,RANDOMIZED CONTROLLED-TRIAL,screening,prostate cancer,prostate-specific antigen,prostate biopsy,early diagnosis},
  language     = {eng},
  number       = {2},
  pages        = {100--108},
  title        = {Population screening for prostate cancer: an overview of available studies and meta-analysis},
  url          = {http://dx.doi.org/10.1111/j.1442-2042.2011.02912.x},
  volume       = {19},
  year         = {2012},
}

Chicago
Lumen, Nicolaas, Valérie Fonteyne, Gert De Meerleer, Piet Ost, Geert Villeirs, Alexandre Mottrie, PIETER DE VISSCHERE, BART DE TROYER, and Willem Oosterlinck. 2012. “Population Screening for Prostate Cancer: An Overview of Available Studies and Meta-analysis.” International Journal of Urology 19 (2): 100–108.
APA
Lumen, N., Fonteyne, V., De Meerleer, G., Ost, P., Villeirs, G., Mottrie, A., DE VISSCHERE, P., et al. (2012). Population screening for prostate cancer: an overview of available studies and meta-analysis. INTERNATIONAL JOURNAL OF UROLOGY, 19(2), 100–108.
Vancouver
1.
Lumen N, Fonteyne V, De Meerleer G, Ost P, Villeirs G, Mottrie A, et al. Population screening for prostate cancer: an overview of available studies and meta-analysis. INTERNATIONAL JOURNAL OF UROLOGY. 2012;19(2):100–8.
MLA
Lumen, Nicolaas, Valérie Fonteyne, Gert De Meerleer, et al. “Population Screening for Prostate Cancer: An Overview of Available Studies and Meta-analysis.” INTERNATIONAL JOURNAL OF UROLOGY 19.2 (2012): 100–108. Print.